Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
33 hedge funds and large institutions have $18.1M invested in Galera Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 8 closing their positions.
32% more capital invested
Capital invested by funds: $13.7M → $18.1M (+$4.42M)
15% less funds holding
Funds holding: 39 → 33 (-6)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$122K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$15.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.21K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$455 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$120K |
| 2 |
Two Sigma Advisers
New York
|
-$52K |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
-$45K |
| 4 |
Two Sigma Investments
New York
|
-$30.7K |
| 5 |
Millennium Management
New York
|
-$24K |
GRTX Hedge Fund Activity: Q3 2022 in Review
33 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q3 2022, worth a combined $18.1M — up 32% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GRTX and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $122K. The largest seller was Renaissance Technologies, cutting an estimated $120K.
- 33 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q3 2022, down from 39 in Q2 2022.
- Funds reported $18.1M of Galera Therapeutics, Inc. Common Stock stock for Q3 2022, up 32% quarter-over-quarter.
- 3 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -5 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q3 2022 was Geode Capital Management, an estimated $122K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $120K sold.
Based on aggregated 13F filings for Q3 2022.